Liver Enzyme Elevations in Rheumatoid Arthritis: Clinical Relevance and Influence on Treatment Strategies
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lard, L.R.; Visser, H.; Speyer, I.; vander Horst-Bruinsma, I.E.; Zwinderman, A.H.; Breedveld, F.C.; Hazes, J.M. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am. J. Med. 2001, 111, 446–451. [Google Scholar] [CrossRef]
- Katchamart, W.; Trudeau, J.; Phumethum, V.; Bombardier, C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis. 2009, 68, 1105–1112. [Google Scholar]
- Conway, R.; Carey, J.J. Risk of liver disease in methotrexate treated patients. World J. Hepatol. 2017, 9, 1092–1100. [Google Scholar] [CrossRef]
- National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2012; Bookshelf ID: NBK547852. [Google Scholar]
- Visser, K.; Van Der Heijde, D.M.F.M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: A systematic review. Clin. Exp. Rheumatol. 2009, 27, 1017–1025. [Google Scholar]
- Wasko, M.C.M.; Dasgupta, A.; Hubert, H.; Fries, J.F.; Ward, M.M. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013, 65, 334–342. [Google Scholar] [CrossRef]
- Hazlewood, G.S.; Barnabe, C.; Tomlinson, G.; Marshall, D.; Devoe, D.; Bombardier, C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: Abridged Cochrane systematic review and network meta-analysis. BMJ 2016, 353, i1777. [Google Scholar] [CrossRef]
- Wessels, J.A.M.; Huizinga, T.W.J.; Guchelaar, H.-J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 2008, 47, 249–255. [Google Scholar] [CrossRef]
- Van Ede, A.E.; Laan, R.F.J.M.; Rood, M.J.; Huizinga, T.W.J.; Van De Laar, M.A.F.J.; Van Denderen, C.J.; Westgeest, T.A.A.; Romme, T.C.; De Rooij, D.-J.R.A.M.; Jacobs, M.J.M.; et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001, 44, 1515–1524. [Google Scholar]
- Kent, P.D.; Luthra, H.S.; Michet, C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J. Rheumatol. 2004, 31, 1727–1731. [Google Scholar]
- Whittle, S.L.; Hughes, R.A. Folate supplementation and methotrexate treatment in rheumatoid arthritis: A review. Rheumatology 2004, 43, 267–271. [Google Scholar]
- Gibofsky, A. Combination therapy for rheumatoid arthritis in the era of biologicals. HSS J. 2006, 2, 30–41. [Google Scholar]
- Sotoudehmanesh, R.; Anvari, B.; Akhlaghi, M.; Shahraeeni, S.; Kolahdoozan, S. Methotrexate hepatotoxicity in patients with rheumatoid arthritis. Middle East. J. Dig. Dis. 2010, 2, 104–109. [Google Scholar]
- Mackenzie, A.H. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis. Cleve Clin. J. Med. 1985, 52, 129–135. [Google Scholar]
- Curtis, J.R.; Beukelman, T.; Onofrei, A.; Cassell, S.; Greenberg, J.D.; Kavanaugh, A.; Reed, G.; Strand, V.; Kremer, J.M. Elevated liver enzyme tests among patients with RA or PsA treated with methotrexate and/or leflunomide. Ann. Rheum. Dis. 2010, 69, 43–47. [Google Scholar]
- Dirven, L.; Klarenbeek, N.B.; van den Broek, M.; van Groenendael, J.H.L.M.; de Sonnaville, P.B.J.; Kerstens, P.M.; Huizinga, T.W.J.; Dijkmans, B.A.C.; Lems, W.F.; Allaart, C.F. Risk of ALT elevation in rheumatoid arthritis patients treated with methotrexate. Clin. Rheumatol. 2013, 32, 585–590. [Google Scholar]
- Schmajuk, G.; Miao, Y.; Yazdany, J.; Boscardin, W.J.; Daikh, D.I.; Steinman, M.A. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014, 66, 1159–1166. [Google Scholar] [CrossRef]
- Singh, J.A.; Saag, K.G.; Bridges, S.L., Jr.; Akl, E.A.; Bannuru, R.R.; Sullivan, M.C.; Vaysbrot, E.; McNaughton, C.; Osani, M.; Shmerling, R.H.; et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016, 68, 1–26. [Google Scholar]
- Kremer, J.M.; Alarcon, G.S.; Lıghtfoot, R.W., Jr.; Willkens, R.F.; Furst, D.E.; Williams, H.J.; Dent, P.B.; Weinblatt, M.E. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Am. Coll. Rheumatol. Arthritis Rheum. 1994, 37, 316–328. [Google Scholar]
- Ujfalussy, I.; Koo, E.; Sesztak, M.; Gergely, P. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z. Rheumatol. 2003, 62, 155–160. [Google Scholar]
- Weınblatt, M.E.; Kaplan, H.; Germain, B.F.; Block, S.; Solomon, S.D.; Merriman, R.C.; Wolfe, F.; Wall, B.; Anderson, L.; Gall, E.; et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994, 37, 1492–1498. [Google Scholar]
- Carlsson Sundbaum, J.; Eriksson, N.; Hallberg, P.; Lehto, N.; Wadelius, M.; Baecklund, E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up. Int. J. Rheum. Dis. 2019, 22, 1226–1232. [Google Scholar] [CrossRef]
- Anvari, B. Methotrexate Hepatotoxicity in Rheumatoid Arthritis: An Analysis of the Physicians’ Policy. Curr. Rheumatol. Rev. 2020, 16, 67–73. [Google Scholar] [CrossRef] [PubMed]
- Visser, K.; Katchamart, W.; Loza, E.; A Martinez-Lopez, J.; Salliot, C.; Trudeau, J.; Bombardier, C.; Carmona, L.; van der Heijde, D.; Bijlsma, J.W.J.; et al. Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 2009, 68, 1086–1093. [Google Scholar] [CrossRef] [PubMed]
- Kremer, J.M.; Phelps, C.T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992, 35, 138–145. [Google Scholar] [CrossRef]
- Rau, R.; Karger, T.; Herborn, G.; Frenzel, H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J. Rheumatol. 1989, 16, 489–493. [Google Scholar]
- Quintin, E.; Scoazec, J.Y.; Marotte, H.; Miossec, P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res. Ther. 2010, 12, R143. [Google Scholar] [CrossRef]
- Kremer, J.M.; Lee, R.G.; Tolman, K.G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 1989, 32, 121–127. [Google Scholar] [CrossRef]
- Walker, A.M.; Funch, D.; Dreyer, N.A.; Tolman, K.G.; Kremer, J.M.; Alarcón, G.S.; Lee, R.G.; Weinblatt, M.E. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993, 36, 329–335. [Google Scholar] [CrossRef]
- Salliot, C.; van der Heijde, D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann. Rheum. Dis. 2009, 68, 1100–1104. [Google Scholar] [CrossRef] [PubMed]
- Suissa, S.; Ernst, P.; Hudson, M.; Bitton, A.; Kezouh, A. DMARDs and risk of serious hepatic adverse events in RA patients. Am. J. Med. 2004, 117, 87–92. [Google Scholar] [CrossRef]
- Rigby, W.F.C.; Lampl, K.; Low, J.M.; Furst, D.E. Review of routine laboratory monitoring for RA patients on biologics/DMARDs. Int. J. Rheumatol. 2017, 2017, 9614241. [Google Scholar] [CrossRef] [PubMed]
- Kremer, J.M.; Genovese, M.C.; Cannon, G.W.; Caldwell, J.R.; Cush, J.J.; Furst, D.E.; Luggen, M.E.; Keystone, E.; Weisman, M.H.; Bensen, W.M.; et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2002, 137, 726–733. [Google Scholar] [CrossRef] [PubMed]
- Singh, J.A. Treatment Guidelines in Rheumatoid Arthritis. Rheum. Dis. Clin. N. Am. 2022, 48, 679–689. [Google Scholar] [CrossRef]
Characteristics | All Patients (n = 33) | Female (n = 19) | Male (n = 14) |
---|---|---|---|
Age (years, mean ± SD) | 66 ± 11 | 68 ± 10 | 64 ± 12 |
Comorbidity (present, %) | 12 (36%) | 7 (37%) | 5 (36%) |
Polytherapy (%) | 15 (45%) | 9 (47%) | 6 (43%) |
MTX monotherapy | 12 (36%) | 7 (37%) | 5 (36%) |
Non-MTX monotherapy | 4 (12%) | 2 (11%) | 2 (14%) |
MTX + other DMARD | 8 (24%) | 5 (26%) | 3 (21%) |
Biologic monotherapy | 2 (6%) | 1 (5%) | 1 (7%) |
MTX + Biologic agent | 7(21%) | 4(23%) | 3(22%) |
Degree of Enzyme Elevation | Number of Patients | Percentage (%) | Female/Male |
---|---|---|---|
1–2 × ULN | 22 | 67% | 6/4 |
2–3 × ULN | 7 | 21% | 5/3 |
>3 × ULN | 4 | 12% | 8/7 |
Total | 33 | 100% | 19/14 |
Treatment Type | All Patients (n = 33) | 1–2 × ULN | 2–3 × ULN | >3 × ULN |
---|---|---|---|---|
MTX monotherapy | 12 | 11 | 1 | 0 |
Non-MTX monotherapy | 4 | 4 | - | - |
MTX + other DMARD | 8 | 5 | 2 | 1 |
Biologic monotherapy | 2 | 1 | 1 | 0 |
MTX + Biologic agent | 7 | 1 | 3 | 3 |
Degree of Enzyme Elevation | All Patients (n = 15) | MTX Monotherapy | Non-MTX Monotherapy | Polytherapy (%) |
---|---|---|---|---|
1–2 × ULN | 8 (53%) | 5 | 2 | 1 |
2–3 × ULN | 6 (40%) | 0 | 0 | 6 |
>3 × ULN | 1 (7%) | 0 | 0 | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Atayan, Y.; Yolbas, S.; Bodakci, E. Liver Enzyme Elevations in Rheumatoid Arthritis: Clinical Relevance and Influence on Treatment Strategies. J. Clin. Med. 2025, 14, 7213. https://doi.org/10.3390/jcm14207213
Atayan Y, Yolbas S, Bodakci E. Liver Enzyme Elevations in Rheumatoid Arthritis: Clinical Relevance and Influence on Treatment Strategies. Journal of Clinical Medicine. 2025; 14(20):7213. https://doi.org/10.3390/jcm14207213
Chicago/Turabian StyleAtayan, Yahya, Servet Yolbas, and Emin Bodakci. 2025. "Liver Enzyme Elevations in Rheumatoid Arthritis: Clinical Relevance and Influence on Treatment Strategies" Journal of Clinical Medicine 14, no. 20: 7213. https://doi.org/10.3390/jcm14207213
APA StyleAtayan, Y., Yolbas, S., & Bodakci, E. (2025). Liver Enzyme Elevations in Rheumatoid Arthritis: Clinical Relevance and Influence on Treatment Strategies. Journal of Clinical Medicine, 14(20), 7213. https://doi.org/10.3390/jcm14207213